PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1536.00 - 1565.00
1090.00 - 1784.00
46.2K / 155.6K (Avg.)
23.48 | 66.41
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
38.10%
Revenue growth at 75-90% of 6203.T's 46.23%. Bill Ackman would push for innovation or market expansion to catch up.
-1.49%
Negative gross profit growth while 6203.T is at 1.68%. Joel Greenblatt would examine cost competitiveness or demand decline.
-38.17%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-24.64%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-27.98%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-28.02%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-28.02%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
14.38%
OCF growth above 1.5x 6203.T's 2.96%. David Dodd would confirm a clear edge in underlying cash generation.
14.38%
FCF growth above 1.5x 6203.T's 2.96%. David Dodd would verify if the firm’s strategic investments yield superior returns.
67.46%
Positive 10Y revenue/share CAGR while 6203.T is negative. John Neff might see a distinct advantage in product or market expansion over the competitor.
-49.63%
Negative 5Y CAGR while 6203.T stands at 10.95%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-22.53%
Negative 3Y CAGR while 6203.T stands at 5.64%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2.05%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-84.89%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-74.03%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
107.45%
Positive growth while 6203.T is negative. John Neff might see a strong advantage in steadily compounding net worth over a decade.
29.24%
5Y equity/share CAGR 1.25-1.5x 6203.T's 21.16%. Bruce Berkowitz confirms if reinvested profits or buybacks explain the superior buildup.
21.55%
3Y equity/share CAGR 1.25-1.5x 6203.T's 19.03%. Bruce Berkowitz confirms timely buybacks or margin improvements drive stronger near-term equity growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9.74%
Firm’s AR is declining while 6203.T shows 17.81%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-21.30%
Both reduce inventory yoy. Martin Whitman suspects a broader move to lean operations or industry slowdown in demand.
-7.12%
Negative asset growth while 6203.T invests at 3.88%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
1.72%
Positive BV/share change while 6203.T is negative. John Neff sees a clear edge over a competitor losing equity.
-11.27%
We’re deleveraging while 6203.T stands at 15.38%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-11.76%
Our R&D shrinks while 6203.T invests at 5.48%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
9.10%
SG&A growth well above 6203.T's 3.96%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.